Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03688685 · ClinicalTrials.gov registry record · Phase 2
A Clinical Study to Evaluate CAD-1883 in Essential Tremor
A Phase 2 study, sponsored by Cadent Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT03688685: Completed Phase 2 study, sponsored by Cadent Therapeutics.
NCT03688685 is a Phase 2 study that has completed, run by Cadent Therapeutics. The registered enrollment target is 25 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03688685, a Phase 2 study, has completed, sponsored by Cadent Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
This is an open-label study designed to evaluate the safety, tolerability and efficacy of CAD-1883, a positive allosteric modulator of the SK channel, administered twice daily orally to adult patients with ET. Patients with the diagnosis of ET based on the Movement Disorder Society (MDS) criteria with a documented severity of tremor based on the clinician-administered TETRAS Performance Subscale are eligible to be enrolled in the study.
Primary Outcome
Number of subjects who experienced TEAEs and the severity of those TEAEs.
Interventions
- DRUG CAD-1883
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2019-01-23 |
| Est. Completion | 2019-09-24 |
| Phase | Phase 2 |
What the finished NCT03688685 record still lists
NCT03688685 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 1 intervention - of which CAD-1883 is the first listed.
NCT03688685 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03688685 about?
NCT03688685 is a clinical study titled "A Clinical Study to Evaluate CAD-1883 in Essential Tremor". This is an open-label study designed to evaluate the safety, tolerability and efficacy of CAD-1883, a positive allosteric modulator of the SK channel, administered twice daily orally to adult patients with ET. Patients with the diagnosis of ET based on the Movement Disorder Society (MDS) criteria wi...
What is the current status of trial NCT03688685?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2019-01-23. Estimated completion is 2019-09-24.
What interventions are being tested in trial NCT03688685?
The interventions under investigation include: CAD-1883 (DRUG).
Who is sponsoring clinical trial NCT03688685?
This trial is sponsored by Cadent Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03688685's enrollment target sits among peer trials
25 1719th of 2000 higher than 245 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI